In the Original Contribution entitled "Efficacy of Rofecoxib, Celecoxib,
and Acetaminophen in Osteoarthritis of the Knee" published in the January
2, 2002, issue of THE JOURNAL (2002;287:64-71), 2 references were cited incorrectly
and 2 were inadvertently omitted. On page 70, in the second column at the
bottom, reference 29 should refer to Mukherjee et al and reference 30 should
refer to Konstam et al (see below). In the third column on that page, second
paragraph, the sentence "It is possible that a higher dose . . . perhaps because
of lack of proportional increase in plasma levels beyond this dose" refers
to citation 31, AHFS Drug Information (previous citation 30) and in the next
paragraph, the first sentence that reads "The efficacy and safety profiles
. . . NSAID-related adverse events."28 should be cited as reference
32. The corresponding corrected references are:
29. Mukherjee D, Nissen SE, Topol EJ. Risk
of cardiovascular events associated with selective COX-2 inhibitors. JAMA.
30. Konstam MA, Weir MR, Reicin A, et al. Cardiovascular
thrombotic events in controlled, clinical trials of rofecoxib. Circulation. 2001;104:2280-2288.
31.AHFS Drug Information,
2000. Bethesda, Md: American Society of Health System Pharmacists;
32. Bloom BS. Direct medical costs of disease
and gastrointestinal side effects during treatment for arthritis. Am J Med. 1988;84:20-24.
In addition, Tables 2 and 3 were printed with errors. In Table 2, the
95% CI for morning stiffness (6 weeks) should read (−34.2 to −23.8).
In Table 3 the first reference to "upper respiratory tract infection" should
instead read "urinary tract infection."
Missing References and Errors in Tables. JAMA. 2002;287(8):989. doi:10.1001/jama.287.8.989